Below are the most recent publications written about "Raloxifene Hydrochloride" by people in Profiles.
-
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Tseng CW, Wong JB. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019 09 03; 322(9):857-867.
-
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017 08; 69(8):1521-1537.
-
Foster SA, Shi N, Curkendall S, Stock J, Chu BC, Burge R, Diakun DR, Krege JH. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health. 2013 Mar 23; 13:15.
-
Schnatz PF, Marakovits KA, Dubois M, O'Sullivan DM. Osteoporosis screening and treatment guidelines: are they being followed? Menopause. 2011 Oct; 18(10):1072-8.
-
Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, Cummings SR. Effect of Raloxifene on all-cause mortality. Am J Med. 2010 May; 123(5):469.e1-7.
-
Stock JL, Mershon JL, Schoenfeld MJ. Review of comparative effectiveness of treatments to prevent fractures. Ann Intern Med. 2008 Jun 03; 148(11):885; author reply 887.
-
Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res. 2008 Jan; 23(1):112-20.
-
Tjia J, Micco E, Armstrong K. Interest in breast cancer chemoprevention among older women. Breast Cancer Res Treat. 2008 Apr; 108(3):435-53.
-
Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Stock JL. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone. 2007 Apr; 40(4):843-51.
-
Meadows ES, Stock J, Johnston JA. Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies. Med Decis Making. 2006 Nov-Dec; 26(6):633-5; author reply 636-7.